Alphyn Secures Key U.S. Patent for Atopic Dermatitis Drug Candidate, Extending IP Protection to 2041
核心洞察
Alphyn Biologics (搜索) received a new U.S. patent from the USPTO covering the active pharmaceutical ingredient in its lead atopic dermatitis (搜索) candidate, providing protection until 2041.
The patent complements the company's existing Zabalafin Hydrogel patent protection extending to 2043, creating comprehensive intellectual property coverage for the topical treatment.
Zabalafin Hydrogel demonstrated strong efficacy and safety in Phase 2a clinical trials and uniquely targets multiple aspects of atopic dermatitis (搜索) including pruritus (搜索), bacterial components, and immuno-inflammatory pathways.
Alphyn Biologics (搜索) has strengthened its intellectual property position for atopic dermatitis (搜索) treatment with a new U.S. patent covering the active pharmaceutical ingredient in its lead therapeutic candidate. The U.S. Patent and Trademark Office (搜索) granted the patent on October 27, 2025, providing protection until 2041 for the topical use of Alphyn's drug raw material in treating atopic dermatitis.
The patent expands Alphyn's existing intellectual property portfolio, which already includes a U.S. patent for Zabalafin Hydrogel drug products with protection extending to 2043. "This is a significant achievement for Alphyn," said CEO Neal Koller. "Together with our previously issued patent for Zabalafin Hydrogel, we have broad protection for the product's composition and methods of use."
Multi-Target Therapeutic Approach Shows Promise
Zabalafin Hydrogel represents a first-in-class Multi-Target Therapeutic being developed for atopic dermatitis (搜索), the most common form of eczema (搜索). The treatment has demonstrated strong efficacy and safety in Phase 2a clinical trials, positioning it as a potential comprehensive solution for long-term, continuous use without safety concerns.
The therapeutic's unique mechanism addresses multiple aspects of atopic dermatitis (搜索) simultaneously. According to Alphyn, Zabalafin Hydrogel directly treats the condition's pruritus (搜索), bacterial components, and immuno-inflammatory pathways - a comprehensive approach that differentiates it from existing treatments.
Regulatory and Commercial Advantages
Both patents will be eligible for listing in the FDA's Orange Book upon regulatory approval of the atopic dermatitis (搜索) drug, providing additional commercial protections. The Orange Book listing system offers pharmaceutical companies extended market exclusivity periods that can significantly impact competitive positioning.
Alphyn's patent portfolio extends beyond the U.S. market, with multiple applications filed globally. The company recently received a Notice of Allowance of Claims on a key patent for Zabalafin Hydrogel from the European Patent Office (搜索), indicating expanding international protection.
Platform Technology and Pipeline Potential
The Zabalafin Platform underlying the company's lead candidate contains multiple bioactive compounds with various mechanisms of action. This multi-target approach supports a broader pipeline of dermatologic therapeutics that Alphyn suggests may offer advantages in efficacy, safety, side effects, patient tolerability, and regulatory marketing authorization.
Alphyn Biologics (搜索) became operational in 2020 and has raised approximately $21 million to advance its dermatology-focused development programs. The clinical-stage company operates from locations in Annapolis, Maryland, and Cincinnati, Ohio, with wholly owned subsidiaries in Australia and Austria.